Literature DB >> 30242265

The emerging role of ADAM metalloproteinases in immunity.

Bart N Lambrecht1,2,3, Matthias Vanderkerken4, Hamida Hammad4,5.   

Abstract

Proteolysis is an irreversible physiological process that can result in the termination or activation of protein function. Many transmembrane proteins that are involved in the cellular communication between immune cells and structural cells - for example, Notch, CD23, CD44, and membrane-anchored cytokines and their receptors - are cleaved by the ADAM (a disintegrin and metalloproteinase) family of enzymes. Here, we review recent insights into the molecular activation, substrate specificity and function of ADAM proteins in the development and regulation of the immune system, with a particular focus on the roles of ADAM10 and ADAM17.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30242265     DOI: 10.1038/s41577-018-0068-5

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  61 in total

1.  Domain integration of ADAM family proteins: Emerging themes from structural studies.

Authors:  Tom Cm Seegar; Stephen C Blacklow
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-23

2.  Open conformation of tetraspanins shapes interaction partner networks on cell membranes.

Authors:  Yihu Yang; Xiaoran Roger Liu; Zev J Greenberg; Fengbo Zhou; Peng He; Lingling Fan; Shixuan Liu; Guomin Shen; Takeshi Egawa; Michael L Gross; Laura G Schuettpelz; Weikai Li
Journal:  EMBO J       Date:  2020-08-16       Impact factor: 11.598

3.  Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.

Authors:  Beiyu Tang; Xue Li; Thorsten Maretzky; Jose Manuel Perez-Aguilar; David McIlwain; Yifang Xie; Yufang Zheng; Tak W Mak; Harel Weinstein; Carl P Blobel
Journal:  FASEB J       Date:  2020-02-26       Impact factor: 5.191

Review 4.  Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.

Authors:  Jianming Wu; Hemant K Mishra; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2019-02-20       Impact factor: 4.962

5.  TAO-kinase 3 governs the terminal differentiation of NOTCH2-dependent splenic conventional dendritic cells.

Authors:  Matthias Vanderkerken; Bastiaan Maes; Lana Vandersarren; Wendy Toussaint; Kim Deswarte; Manon Vanheerswynghels; Philippe Pouliot; Liesbet Martens; Sofie Van Gassen; Connie M Arthur; Margaret E Kirkling; Boris Reizis; Daniel Conrad; Sean Stowell; Hamida Hammad; Bart N Lambrecht
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-19       Impact factor: 11.205

Review 6.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.

Authors:  Maria Esperanza Rodriguez-Ruiz; Ilio Vitale; Kevin J Harrington; Ignacio Melero; Lorenzo Galluzzi
Journal:  Nat Immunol       Date:  2019-12-23       Impact factor: 25.606

7.  ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-β1.

Authors:  Masataka Umeda; Nobuya Yoshida; Ryo Hisada; Catalina Burbano; Seo Yeon K Orite; Michihito Kono; Vasileios C Kyttaris; Suzanne Krishfield; Caroline A Owen; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

Review 8.  New insights into the molecular mechanisms of axon guidance receptor regulation and signaling.

Authors:  Yixin Zang; Karina Chaudhari; Greg J Bashaw
Journal:  Curr Top Dev Biol       Date:  2021-01-18       Impact factor: 4.897

9.  Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils.

Authors:  Kristin M Snyder; Camille A McAloney; Joshua S Montel; Jaime F Modiano; Bruce Walcheck
Journal:  Vet Immunol Immunopathol       Date:  2020-11-17       Impact factor: 2.046

10.  Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.

Authors:  Yeni Romero; Randi Wise; Anna Zolkiewska
Journal:  Cancer Immunol Immunother       Date:  2019-12-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.